A new study published in the Journal of American Medical Association showed that dupilumab (Dupixent), used for treating ...

Investing.com -- Nektar Therapeutics (NASDAQ: NKTR) stock surged 20% following the company’s announcement that it will present top-line data from its REZOLVE-AD Phase 2b clinical trial for atopic ...

Shares of Nektar Therapeutics soared after the company said it would release topline data from a study of its atopic dermatitis treatment rezpegaldesleukin. The stock was up 31% at $12.49 in Monday's ...

Nektar Therapeutics said it would release topline data from a study of its atopic dermatitis treatment rezpegaldesleukin on Tuesday. Shares climbed 27% to $12.15 in after-hours trading Monday.

Three months after the US Sofdra launch, prescriptions have exceeded Botanix Pharmaceuticals' expectations. What are they ...

The FDA pushed back the Prescription Drug User Fee Act action date for ruxolitinib cream (Opzelura) by three months to September 19, 2025. The extension will allow regulators time to review additional ...

Shea butter has historically been used for skin ailments for centuries. Learn the wide range of shea butter benefits and how ...

Nektar Therapeutics shares jumped 35.3% in extended trading Monday after the company said it would release topline results ...

Sanofi and Regeneron’s Dupixent (dupilumab) has been approved by the US Food and Drug Administration (FDA) to treat bullous ...

A team led by the University of Exeter, and including researchers from King's College London, has been awarded a £3.3 million grant from the Medical ...

A team of researchers led by the University of Exeter have been awarded a £3.3 million grant by the Medical Research Council ...

Incyte INCY announced that the FDA has extended the review period for the supplemental new drug application (sNDA) for ...